Related Experiment Video
Updated: Jul 6, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
[Inflammatory myofibroblastic tumor. Case report].
Pablo Garrido Abad1, A Coloma del Peso, M Jiménez Gálvez
1Servicio de Urología, Hospital de La Princesa, Madrid, España. pgabad@hotmail.com
Archivos Espanoles De Urologia
|April 15, 2008
Summary
A rare benign bladder tumor, inflammatory myofibroblastic tumor, was diagnosed in a 30-year-old woman. Transurethral resection (TUR) is the optimal treatment, offering an excellent long-term prognosis for this uncommon condition.
Area of Science:
- Uropathology
- Oncology
- Surgical Pathology
Background:
- Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm of mesenchymal origin.
- While IMT can occur in various locations, bladder involvement is exceptionally uncommon.
- Accurate diagnosis is crucial to differentiate IMT from malignant bladder neoplasms.
Observation:
- A 30-year-old woman presented with recurrent urinary tract infections.
- Abdominal ultrasound revealed an incidental bladder mass.
- Histopathological examination post-transurethral resection (TUR) confirmed the diagnosis of IMT.
Findings:
- The bladder mass was diagnosed as an inflammatory myofibroblastic tumor.
- This benign tumor, also known as inflammatory pseudotumor or pseudosarcoma, has a mesenchymal origin.
- The patient's presentation included recurrent urinary tract infections and an incidentally discovered bladder mass.
Implications:
- Transurethral resection (TUR) is the recommended treatment for bladder IMT.
- Early diagnosis and appropriate management are essential to avoid misdiagnosis as malignancy.
- Patients with bladder IMT treated with TUR can expect an excellent long-term prognosis.